Synthesis of cyclic hydrocarbons via intramolecular coupling of bis-pentadienyl iron tricarbonyl cations

A general synthesis for the preparation of medium sized cycloalkanes having 1,2-butadienyl substituents is described. The reaction sequence involved acylation of butadiene-iron tricarbonyl with a diacid chloride, reduction of the resultant diketone to a diol derivative and conversion with HBF₄ to an acyclic bis-pentadienyl Fe(C0)₃ dicationic complex. Upon treatment with zinc the dication undergoes intramolecular ring closure to afford the bis-Fe(C0)₃ complex of the 1,2-dibutadienyl cycloalkane. Five-, six- and ten-membered cyclolalkene derivatives have been prepared in this manner.     

Field ionization mass spectrometry—II: Benzyloxycarbonyl and t-butyloxycarbonyl derivatives of some simple peptides

A brief discussion is given of some factors that merit consideration in the analysis of peptides by mass spectrometry, with emphasis on sequence determination. The first systematic study of simple peptides by field ionization (FI) is described, and comparison made with the corresponding electron-impact (EI) ionization spectra, both at low resolution (approx. 1500). The substances examined were either benzyloxycarbonyl or t-butyloxycarbonyl derivatives of di-through pentapeptide methyl esters, containing the amino acids glycine, alanine, leucine, serine, threonine, proline and tyrosine. The incidences of sequence-characteristic cleavage peaks and rearrangement ion peaks were both slightly lower in the FI than the EI spectra, although the peak relative intensities generally were higher under FI conditions.     

Interactions of halichondrin B and eribulin with tubulin

Compounds that modulate microtubule dynamics include highly effective anticancer drugs, leading to continuing efforts to identify new agents and improve the activity of established ones. Here, we demonstrate that [(3)H]-labeled halichondrin B (HB), a complex, sponge-derived natural product, is bound to and dissociated from tubulin rapidly at one binding site per αβ-heterodimer, with an apparent K(d) of 0.31 μM. We found no HB-induced aggregation of tubulin by high-performance liquid chromatography, even following column equilibration with HB. Binding of [(3)H]HB was competitively inhibited by a newly approved clinical agent, the truncated HB analogue eribulin (apparent K(i), 0.80 μM) and noncompetitively by dolastatin 10 and vincristine (apparent K(i)'s, 0.35 and 5.4 μM, respectively). Our earlier studies demonstrated that HB inhibits nucleotide exchange on β-tubulin, and this, together with the results presented here, indicated the HB site is located on β-tubulin. Using molecular dynamics simulations, we determined complementary conformations of HB and β-tubulin that delineated in atomic detail binding interactions of HB with only β-tubulin, with no involvement of the α-subunit in the binding interaction. Moreover, the HB model served as a template for an eribulin binding model that furthered our understanding of the properties of eribulin as a drug. Overall, these results established a mechanistic basis for the antimitotic activity of the halichondrin class of compounds.